The Complete Annual Blood Panel: What to Test Every Year (and What to Skip)
What blood work should you actually get every year? The complete annual panel — the foundational tests, the high-value markers most physicals skip, and the trendy tests that aren't worth your money.
Key takeaways
- The 'standard' annual physical panel — a basic metabolic panel, a blood count, and a cholesterol panel — is a reasonable floor, but it leaves out several of the markers that best predict long-term cardiometabolic risk.
- The highest-value additions most physicals skip are ApoB, Lp(a), fasting insulin (for HOMA-IR), and hs-CRP — markers a preventive cardiologist or metabolic specialist routinely orders.
- Lp(a) is largely genetic and stable for life, so it generally only needs to be measured once — a rare 'test it a single time' marker that can meaningfully change your risk picture.
- More tests is not better. Every marker carries a false-positive rate, so a giant unfocused panel almost guarantees a few meaningless flags. The goal is the right tests, ordered with intent.
- Some popular tests are low-yield or actively discouraged for healthy people — IgG 'food sensitivity' panels, broad untargeted micronutrient screens, and routine cancer-marker blood tests in average-risk adults.
- Frequency matters as much as selection: most markers are worth checking yearly, some (like Lp(a)) once, and stable values don't need constant re-testing.
In this article
- What the “Standard” Physical Actually Covers
- Tier 1: The Foundation (Worth It for Almost Everyone)
- Tier 2: The High-Value Additions Most Physicals Skip
- How Often to Test What
- What to Skip (or Approach With Caution)
- How to Actually Get These Done
- Where This Leaves Us
- Frequently Asked Questions (FAQs)
Ask most people what’s in their annual bloodwork and they don’t really know — the doctor ordered “the usual,” nothing came back red, and that was that. The trouble is “the usual” is a thin panel, and the markers it omits include some of the best early-warning signs we have for the conditions that actually shorten lives.
The wellness industry’s answer — test everything, the longer the better — is the opposite mistake, buying false positives and anxiety more than insight. The right approach is in between: a deliberate panel, built in tiers, that covers what matters and skips what doesn’t. Here’s how a pharmacist would assemble it.
What the “Standard” Physical Actually Covers
A typical physical orders some mix of a complete blood count (CBC), a comprehensive metabolic panel (CMP), and a lipid panel — sometimes a TSHTSH (thyroid-stimulating hormone) A pituitary hormone measured to check how well the thyroid is working.. That’s a reasonable floor: the CBC screens for anemia and blood disorders, the CMP checks kidney and liver function, electrolytes, and fasting glucose, and the lipid panel gives total, LDL, HDLHDL (high-density lipoprotein) Often called "good cholesterol." HDL particles ferry cholesterol away from artery walls back to the liver. Higher levels are generally linked to lower cardiovascular risk, though HDL function matters more than the number alone., and triglyceridestriglycerides The main form of fat carried in the blood and stored in fat tissue. High levels travel with insulin resistance and cardiovascular risk, and they respond strongly to diet, alcohol, and omega-3 dose..
What it misses is the revealing layer. A standard lipid panel can look reassuring while hiding real cardiovascular risk, because LDL is an imperfect measure of the harmful particle count — the issue we cover in ApoB versus LDL and why “your cholesterol is fine” can mislead. And a single fasting glucose can sit in the normal range while insulin resistance builds underneath for years. The standard panel isn’t wrong — just incomplete for anyone serious about prevention.
Foundation — for almost everyone
High-value additions — most physicals skip
Generally skip — average-risk adults
Built with intent — a deliberate panel beats a maximal one. Every marker carries a false-positive rate, so a longer list mostly buys false alarms. Bring your selection to a clinician who can tailor it to your history and read the results in context. Educational tool, not medical advice.
Tier 1: The Foundation (Worth It for Almost Everyone)
These are the broadly useful, inexpensive, widely available tests that belong on nearly everyone’s annual draw.
- Complete blood count (CBC). Screens for anemia, signs of infection or inflammation, and blood-cell abnormalities.
- Comprehensive metabolic panel (CMP). Kidney function (creatinine, eGFReGFR (estimated glomerular filtration rate) A calculation from a blood creatinine test that estimates how well the kidneys are filtering waste. A declining eGFR is the primary indicator of worsening kidney function.), liver enzymes (ALT, AST), electrolytes, and fasting glucose. The liver enzymes are quietly important — they’re often the first hint of fatty liver disease (MASLD), though a normal ALT doesn’t rule it out.
- Lipid panel. Total cholesterol, LDL, HDL, triglycerides — the baseline cardiovascular screen, best interpreted against risk-based targets rather than the lab’s “normal” flag.
- HbA1cHbA1c (hemoglobin A1c) A blood test that shows your average blood sugar over the past ~3 months. plus fasting glucose. HbA1c reflects roughly three months of average blood sugar. The US Preventive Services Task Force recommends screening adults 35–70 who carry extra weight, and the diagnostic thresholds are worth knowing: fasting glucose under 100 mg/dL is normal, 100–125 is prediabetes; HbA1c of 5.7–6.4% is prediabetes, 6.5% or higher is diabetes.
- TSH. A reasonable thyroid screen, particularly with relevant symptoms or a family history.
This foundation is cheap, standardized, and covers a lot of ground. For many healthy people it’s most of what they need — provided it’s read correctly.
Tier 2: The High-Value Additions Most Physicals Skip
This is where a generic checkup becomes a real risk assessment. None of these is exotic; they’re routine in preventive cardiology and metabolic medicine, yet they rarely appear on a standard physical.
- ApoB. A direct count of atherogenic (artery-clogging) particles, and a better predictor of cardiovascular risk than LDL cholesterol alone. If you add one cardiac marker beyond the standard panel, this is the one. See ApoB versus LDL.
- Lp(a). A largely genetic, independent cardiovascular risk factor that standard panels ignore. The European Atherosclerosisatherosclerosis The slow buildup of fatty plaque inside artery walls that narrows and stiffens them over time. Society recommends measuring it at least once in adulthood — it raises risk even when LDL is controlled, and most people with high levels have no idea. Since it’s genetically set, one measurement usually suffices. More in Lp(a): the risk factor your doctor probably never tested.
- Fasting insulin (for HOMA-IRHOMA-IR A simple score from fasting glucose and insulin that estimates how insulin-resistant you are.). Paired with fasting glucose, fasting insulin lets you calculate HOMA-IR, an estimate of insulin resistance that often turns abnormal years before glucose does. It’s one of the earliest windows into metabolic trouble.
- hs-CRPCRP (C-reactive protein) A blood marker of inflammation made by the liver. The high-sensitivity version (hs-CRP) is used for heart-risk assessment.. High-sensitivity C-reactive protein, a marker of low-grade inflammation. The CDC/AHA framework reads it in risk tiers — under 1 mg/L lower risk, 1–3 average, above 3 higher — making it a risk-stratification tool rather than a simple pass/fail. See hs-CRP and metabolic health.
- Vitamin D (25-OH). Reasonable to check if you have a reason to be low, with the honest catch that the “right” target is genuinely debated and has shifted over time — the Endocrine Society now advises against routine testing in healthy adults. Useful for identifying real deficiency; not a number to obsess over.
- Ferritin and iron studies. Worth adding for menstruating women, anyone with fatigue, or those on plant-heavy diets — a wide “normal” range can hide low-iron states at the bottom and inflammatory or metabolic signals at the top.
Add ApoB, Lp(a), fasting insulin, and hs-CRP to the foundation and you’ve covered the cardiometabolic story far better than a standard physical does — for a modest extra cost.
How Often to Test What
Selection is half the job; frequency is the other half.
- Annually for most of the foundation and cardiometabolic additions — lipids/ApoB, HbA1c, fasting glucose and insulin, hs-CRP, CBC, CMP — enough to see a trend without over-testing.
- Once (usually for life) for Lp(a), since it’s genetically determined and stable.
- On a shorter interval for anything you’re actively trying to move — rechecking LDL/ApoB or HbA1c a few months after a diet, exercise, or medication change.
- Less often for stable, reassuring values with no symptoms or risk change; a yearly TSH in an asymptomatic person adds little.
The principle: test frequently enough to catch a trend, not so often that you’re chasing noise.
What to Skip (or Approach With Caution)
A smart panel is defined as much by what it leaves out. For healthy, average-risk people, these are generally low-yield:
- IgG “food sensitivity” panels. Not validated to diagnose food intolerance — major allergy organizations advise against them. A positive IgG usually just reflects exposure, and acting on it leads to needless dietary restriction.
- Broad, untargeted micronutrient screens. Testing every vitamin with no specific indication mostly surfaces incidental abnormalities that don’t change management. Test for a deficiency when there’s a reason to suspect one.
- Routine cancer-marker blood tests (CA-125, CEA) in asymptomatic, average-risk people — not recommended for general screening, since they generate false positives and rarely catch disease early. (PSAPSA (prostate-specific antigen) A blood protein made by the prostate, tracked as a screening and monitoring marker for prostate enlargement and prostate cancer. is a shared-decision conversation, not an automatic add.)
- Hormone and heavy-metal panels without symptoms or exposure history. High cost, low yield, and a reliable source of confusing results.
The logic is the screening principle behind evidence-based care: a test earns its place when the result would change what you do. If a flag wouldn’t alter your management, it mostly creates work and worry.
How to Actually Get These Done
You have two routes. Bring this list to your physical and ask your clinician to add the Tier 2 markers — many will, especially with a family history or existing risk factors. Or order them yourself: direct-to-consumer labs now offer ApoB, Lp(a), fasting insulin, and hs-CRP without a referral, exactly the gap they fill. Our guide to direct-to-consumer lab testing walks through the options, and for testing before or during GLP‑1GLP‑1 (glucagon-like peptide-1) A gut hormone released after eating that boosts insulin, slows the stomach, and signals fullness. Drugs like semaglutide mimic it. therapy we cover that panel in GLP‑1 blood work.
Whichever route you take, results are only as good as their interpretation: a number in isolation is a data point; read alongside your history, your other markers, and your trend, it’s information you can act on.
Where This Leaves Us
The best annual panel is a deliberate one: start with the foundation almost everyone benefits from, add the cardiometabolic markers a standard physical skips, test each at a sensible interval, and leave off the trendy extras that generate noise. The result is informative without being bloated — flagging what’s worth acting on and sparing you the false alarms.
Then close the loop the way these markers are meant to be used: not as a number to file away, but as input for a decision made with a clinician who can see the whole picture. Using it with intent is what turns a yearly blood draw into something that actually protects your health.
A note on individualization: This is a general framework for healthy adults, not a personalized prescription. Your age, sex, family history, existing conditions, medications, and symptoms all change which tests matter and how often — for example, pregnancy, kidney disease, or a strong family history of early heart disease each shift the list. Use this as a starting point for a conversation with your clinician, who can tailor the panel to you.
Frequently asked questions (FAQ)
What blood tests should I get every year?
A solid annual foundation is a complete blood count, a comprehensive metabolic panel (kidney, liver, electrolytes), a lipid panel, HbA1c with fasting glucose, and usually a TSH. The high-value additions that most physicals skip — and that are worth requesting — are ApoB, fasting insulin, and hs-CRP, plus Lp(a) at least once.
What's the difference between the standard physical panel and a 'complete' panel?
A standard physical usually covers a metabolic panel, blood count, and basic cholesterol. A more complete panel adds the markers that better predict cardiometabolic risk — ApoB and Lp(a) for cardiovascular risk, fasting insulin for insulin resistance, and hs-CRP for inflammation — which are routine in preventive cardiology but often left off a general checkup.
How often should I get blood work done?
Most markers are reasonable to check once a year. Lp(a) is largely genetic and generally only needs to be measured once in a lifetime. Stable, normal values don't need frequent re-testing, while markers you're actively trying to change — like LDL or HbA1c after a lifestyle or medication change — are worth rechecking on a shorter interval set with your clinician.
Which blood tests are a waste of money?
For healthy, average-risk people, IgG 'food sensitivity' panels (not validated to diagnose food intolerance), broad untargeted vitamin and micronutrient screens, and routine cancer-marker blood tests are generally low-yield or discouraged. They tend to produce confusing or false-positive results without changing what you'd actually do.
Can I order a complete annual panel myself without a doctor?
Yes. Direct-to-consumer lab services let you order most of these markers — including ApoB, Lp(a), fasting insulin, and hs-CRP — without a physician referral, then visit a partner lab for the draw. It's still wise to review the results with a clinician or pharmacist who can interpret them in the context of your full health picture.
The pharmacist's bottom line
A good annual panel isn't about testing everything — it's about testing the right things with intent. The standard physical draws a reasonable floor (a metabolic panel, a blood count, a basic lipid panel, often a thyroid check), but it routinely omits the markers that matter most for the conditions that actually shorten lives: ApoB and Lp(a) for cardiovascular risk, fasting insulin for the insulin resistance that precedes diabetes by years, and hs-CRP for inflammation. Adding those four turns a generic checkup into a genuine risk assessment. Just as important is restraint in the other direction: a sprawling panel of trendy tests mostly buys you false positives, anxiety, and follow-up costs, because every test flags some healthy people by chance. So build deliberately — a foundation everyone benefits from, a high-value second tier for cardiometabolic risk, sensible re-testing intervals, and a short list of things to skip unless there's a specific reason. Then do the part that actually matters: take the results to a clinician who can read them in context and help you act on the ones that change your trajectory. The tests are easy. Using them well is the skill.
Sources (5)
- 1. US Preventive Services Task Force; Davidson KW, Barry MJ, Mangione CM, et al. Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(8):736–743.
- 2. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20–S42.
- 3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/Multisociety Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019;73(24):e285–e350.
- 4. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 2022;43(39):3925–3946.
- 5. Pearson TA, Mensah GA, Alexander RW, et al. Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499–511.
About the author
Was this article helpful?
Enjoyed this one?
Get more breakdowns like this, straight to your inbox
Written by PharmDs, free, no spam — new articles land in your inbox before they hit the feed.
Free. No spam. Unsubscribe anytime.
Order your own labs
Affiliate links. We may earn a commission at no cost to you.